Q1 Earnings Forecast for VKTX Issued By HC Wainwright

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for Viking Therapeutics in a research note issued to investors on Thursday, February 12th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will post earnings of ($0.58) per share for the quarter. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.72) EPS and FY2026 earnings at ($2.75) EPS.

Several other research firms have also recently commented on VKTX. Canaccord Genuity Group raised their target price on Viking Therapeutics from $106.00 to $107.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Wednesday, January 21st. Cantor Fitzgerald set a $105.00 target price on shares of Viking Therapeutics in a research note on Thursday, October 23rd. Zacks Research downgraded shares of Viking Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating for the company in a report on Friday, October 24th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Viking Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $87.80.

Viking Therapeutics Trading Down 4.9%

Shares of NASDAQ:VKTX opened at $29.00 on Monday. The firm’s 50 day moving average is $33.13 and its two-hundred day moving average is $32.57. The firm has a market capitalization of $3.35 billion, a P/E ratio of -9.12 and a beta of 0.76. Viking Therapeutics has a 52 week low of $18.92 and a 52 week high of $43.15.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.49). During the same quarter in the previous year, the company posted ($0.32) EPS.

Insider Buying and Selling at Viking Therapeutics

In related news, COO Marianna Mancini sold 57,661 shares of Viking Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $32.98, for a total value of $1,901,659.78. Following the transaction, the chief operating officer directly owned 409,190 shares in the company, valued at $13,495,086.20. The trade was a 12.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Brian Lian sold 233,409 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $32.96, for a total value of $7,693,160.64. Following the sale, the chief executive officer directly owned 2,499,291 shares in the company, valued at $82,376,631.36. This trade represents a 8.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 364,731 shares of company stock valued at $12,053,627. 4.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in VKTX. The Manufacturers Life Insurance Company raised its holdings in shares of Viking Therapeutics by 8.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 24,272 shares of the biotechnology company’s stock valued at $854,000 after acquiring an additional 1,914 shares during the period. Soros Fund Management LLC acquired a new stake in Viking Therapeutics during the 4th quarter valued at $3,166,000. CANADA LIFE ASSURANCE Co raised its stake in Viking Therapeutics by 23.1% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 14,302 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 2,682 shares during the period. Commerce Bank grew its holdings in shares of Viking Therapeutics by 4.8% during the fourth quarter. Commerce Bank now owns 14,767 shares of the biotechnology company’s stock valued at $520,000 after buying an additional 680 shares in the last quarter. Finally, Quattro Advisors LLC purchased a new position in shares of Viking Therapeutics during the fourth quarter valued at $37,000. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Viking Therapeutics News Roundup

Here are the key news stories impacting Viking Therapeutics this week:

• Positive Sentiment: Company fast‑tracked oral VK2735 into Phase III obesity trials, a material clinical de‑risking and commercialization signal that prompted a sharp rally in headlines and investor enthusiasm. Viking Therapeutics (VKTX) Is Up 16.0% After Fast-Tracking VK2735 Into Phase III Trials – Has The Bull Case Changed?
• Positive Sentiment: Management outlined dual Phase III obesity programs and maintenance regimens for VK2735, giving investors a clearer late‑stage development plan and multiple potential commercialization paths. Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
• Neutral Sentiment: Coverage and valuation checks are proliferating (analysis pieces and retrospectives on historical returns), which can broaden investor interest but don’t change clinical or financial fundamentals. Viking Therapeutics (VKTX) Valuation Check After Q4 2025 Earnings And Obesity Pipeline Progress
• Neutral Sentiment: Media and transcript coverage (earnings call transcripts, long‑term return pieces) are available for deeper diligence but are informational rather than new catalysts. Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results showed a wider‑than‑expected loss (EPS miss) which raises near‑term cash‑burn and financing questions; that financial disappointment likely prompted profit‑taking after the clinical rally. VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates
• Negative Sentiment: Analysts (HC Wainwright) continue to model losses for upcoming quarters/years, reinforcing the expectation that Viking will need to fund late‑stage development — a potential dilution risk that can cap upside until Phase III readouts or financing clarity. MarketBeat VKTX overview / analyst note

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.